Business Context and Reporting Period
Company: MRI Interventions, Inc. (Note: Request metadata listed "Clearpoint Neuro, Inc.", but the filing text identifies the registrant as MRI Interventions, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: June 11, 2012
Event: Material modification to rights of security holders and establishment of terms for Series A Convertible Preferred Stock.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, or margin data. It focuses on debt restructuring and capital structure terms.
- Outstanding Debt Balance: $4,338,601 (as of February 2, 2012, including principal and accrued interest).
- Original Loan Amount: $3,500,000 (borrowed in late 2009).
- Interest Rate: Reduced from 10% per year to 0% effective February 2, 2012.
- Maturity Date: Extended by three years to October through December 2014.
- Conversion Price: $8.00 per share (subject to adjustment in qualified financings).
- Liquidation Preference: $8.00 per share of Series A Convertible Preferred Stock.
Material Changes Versus Prior Period
Effective February 2, 2012, the Company amended its loan agreement with Boston Scientific Corporation:
- Accrued interest was capitalized into the principal balance.
- The interest rate was reduced to 0%.
- The maturity date was extended by three years.
On June 11, 2012, the Board established the terms for "Series A Convertible Preferred Stock" to serve as the conversion vehicle for the notes if Boston Scientific elects to convert outside of a qualified financing. No shares have been issued, and no Certificate of Designations has been filed with the State of Delaware as of the report date.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to file a Certificate of Designations only if and when Boston Scientific elects to convert its notes into the Series A Convertible Preferred Stock.
Key Terms and Contingencies:
- Conversion Trigger: Notes are convertible at Boston Scientific's option prior to maturity or a "qualified initial public offering" (defined as an offering with gross proceeds of at least $20,000,000).
- Qualified Financing: If conversion occurs during a qualified financing, the conversion price is the lower of $8.00 or the price paid by new investors.
- Anti-Dilution: The conversion price adjusts downward if the Company sells common stock at a price lower than the prevailing conversion price.
- Voting Rights: Holders of Series A stock have specific voting rights regarding amendments to the certificate of incorporation and recapitalization transactions that adversely affect their preferences.
Investor Verification Checklist
- Verify the current status of the $4,338,601 debt obligation to Boston Scientific.
- Confirm whether Boston Scientific has elected to convert the notes into Series A Convertible Preferred Stock or common stock.
- Check if a Certificate of Designations for the Series A Convertible Preferred Stock has been filed with the Delaware Secretary of State.
- Monitor for any "qualified financing" or "qualified initial public offering" that would trigger automatic conversion or price adjustments.
- Review the Company's liquidity position given the 0% interest rate extension and the potential dilution from future conversions.